Enterprise Value

304M

Cash

21.9M

Avg Qtr Burn

N/A

Short % of Float

8.18%

Insider Ownership

13.10%

Institutional Own.

89.57%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Belrapzo (Bendamustine hydrochloride injection) Details
CLL (Chronic Lymphocytic Leukemia) and NHL (non-Hodgkins lymphoma)

Approved

Quarterly sales

Approved

Quarterly sales

Vasopressin Details
Vasodilary shock

Approved

Quarterly sales

Approved

Quarterly sales

Landiolol Details
Supraventricular tachycardia

NDA

FDA meeting